Enzymatica AB (STU:EN9) ROCE %: -43.37% (As of Mar. 2026)


STU:EN9 Enzymatica AB STU:EN9
50 GF Score
Price €0.20
GF Value €0.16
! 2 Warning Signs
View Full Analysis

What is Enzymatica AB ROCE %?

Enzymatica AB STU:EN9 +11.80% 50 ROCE % is -43.37% as of Mar. 2026. GuruFocus rates STU:EN9 with a GF Score™ of 50/100 and a GF Value™ of €0.16. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Enzymatica AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -43.37%.

Enzymatica AB  (STU:EN9) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Enzymatica AB ROCE % Related Terms

Enzymatica AB ROCE % Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB ROCE % Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -38.00 -47.99 -39.13 -37.74 -35.46

Enzymatica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.06 -37.11 -22.11 -30.28 -43.37
STU:EN9
50GF Score
Enzymatica AB STU:EN9
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB ROCE % Calculation

Enzymatica AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-4.757/( ( (16.972 - 1.55) + (13.047 - 1.635) )/ 2 )
=-4.757/( (15.422+11.412)/ 2 )
=-4.757/13.417
=-35.46 %

Enzymatica AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-4.916/( ( (13.047 - 1.635) + (11.89 - 0.631) )/ 2 )
=-4.916/( ( 11.412 + 11.259 )/ 2 )
=-4.916/11.3355
=-43.37 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -43.37% mean?
Enzymatica AB (STU:EN9) has a ROCE % of -43.37% as of Mar. 2026.
Is Enzymatica AB's ROCE % too high?
Enzymatica AB's current ROCE % is -43.37%. Overall, Enzymatica AB has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's ROCE % compare to ZTS?
Enzymatica AB's ROCE % of -43.37% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current ROCE % is -43.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Enzymatica AB (STU:EN9) has a current ROCE % of -43.37%. The stock's GF Value™ is €0.16, compared to a current price of €0.20 — trading 24.4% above its estimated fair value. The current ROCE % is -43.37%. Enzymatica AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Enzymatica AB (STU:EN9), the current ROCE % is -43.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (STU:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.20 is trading 24.4% above its estimated GF Value™ of €0.16.

Key valuation signals for STU:EN9:

  • ROCE %: -43.37%
  • GF Value™: €0.16 vs. price of €0.20 (24.4% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the STU:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Other Exchanges ENZY:SwedenEN9:Germany
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
50GF Score

Get the complete analysis for STU:EN9

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.16
GF Value